About this Journal Submit a Manuscript Table of Contents
Advances in Urology
Volume 2012 (2012), Article ID 653652, 7 pages
http://dx.doi.org/10.1155/2012/653652
Review Article

The Use of Regenerative Medicine in the Management of Invasive Bladder Cancer

1Southern Alberta Institute of Urology, University of Calgary, Alberta, Canada T2V 1P9
2The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21287-2101, USA
3University of Chicago Medical Center, Chicago, IL 60637, USA

Received 11 June 2012; Accepted 1 August 2012

Academic Editor: Nan-Haw Chow

Copyright © 2012 Matthew E. Hyndman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Muscle invasive and recurrent nonmuscle invasive bladder cancers have been traditionally treated with a radical cystectomy and urinary diversion. The urinary diversion is generally accomplished through the creation of an incontinent ileal conduit, continent catheterizable reservoir, or orthotopic neobladder utilizing small or large intestine. While radical extirpation of the bladder is often successful from an oncological perspective, there is a significant morbidity associated with enteric interposition within the genitourinary tract. Therefore, there is a great opportunity to decrease the morbidity of the surgical management of bladder cancer through utilization of novel technologies for creating a urinary diversion without the use of intestine. Clinical trials using neourinary conduits (NUC) seeded with autologous smooth muscle cells are currently in progress and may represent a significant surgical advance, potentially eliminating the complications associated with the use of gastrointestinal segments in the urinary reconstruction, simplifying the surgical procedure, and greatly facilitating recovery from cystectomy.